After a series of acquisitions and an activist investor’s accusation of overspending, Pfizer is exploring an opportunity to ...
Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
Keurig Dr Pepper brings in Drew Panayiotou to accelerate digital marketing and Andrew Springate takes a new role.
One company value investors might notice is Pfizer (PFE). PFE is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 9.16, which compares to ...
Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...
On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.72 which represents a decrease of $-0.74 or -2.69% from the prior close of $27.46. The stock opened at $27.11 and touched a low ...
Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...
Pfizer India expanding R&D, manufacturing, and adult vaccination initiatives, showcasing commitment to the country's ...